Family health history and pharmacogenomics show cross generation premature amitriptyline discontinuation is associated with CYP2C19 loss of-function enrichment
FHH of medication response can highlight individuals enriched for pharmacogenomic variants. This is a clinically useful finding, which may flag psychiatric patients with a two-generation history of early amitriptyline discontinuation or intolerance as a priority for pharmacogenomic testing. This study demonstrates the potential of integrating FHH into clinical pharmacogenomics for actionable insights.
Authors
- Damian Smedley (ORCID: https://orcid.org/0000-0002-5836-9850)
- Emma Forton Magavern (ORCID: https://orcid.org/0000-0003-0699-6411)
- Gabriel Marengo (ORCID: https://orcid.org/0009-0004-9420-8239)
- Mark J. Caulfield (ORCID: https://orcid.org/0000-0001-9295-3594)
- Maia Megase (ORCID: https://orcid.org/0009-0004-4797-9794)
Institutions
- Queen Mary University of London (GB)
- William Harvey Research Institute (GB)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1038/s43856-025-01156-3
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Alnylam Pharmaceuticals
- Queen Mary University of London
- Broad Institute
- Barts Charity
- Maze Therapeutics
- National Institute for Health and Care Research
- King's College London
- University of Glasgow
- Public Health England
- Novo Nordisk
- Barts Health NHS Trust
- Medical Research Council